Klarsen specializes in data marketing for customer winning and engagement. Thanks to its qualified data and proprietary technologies, it allows its customers to increase their marketing performance and net sales. Klarsen disposes of proprietary assets and qualified and reactive databases, in its network of partners and on its own.

Employees

Sector

IT Services & Consulting

More about the company

Quotes

Date	Price	Change	Volume
11/11/26	€0.3990	-0.25%	13,206
10/11/26	€0.4000	-4.53%	4,173
09/11/26	€0.4190	-2.56%	2,199
06/11/26	€0.4300	-4.23%	30,821
05/11/26	€0.4490	-0.22%	50

Real-time Euronext Paris

More quotes

Market Closed - Euronext Paris 16:55:00 11/11/2026 GMT			5-day change	1st Jan Change
0.3990 ^EUR	-0.25%		-11.33%	-54.03%

10-22	Klarsen Reports Earnings Results for the Half Year Ended June 30, 2026	CI
08-26	Klarsen Reports Earnings Results for the Full Year Ended December 31, 2025	CI

Market Cap	1.32M 1.47M 1.22M 1.1M 2.09M 138M 2.14M 14.64M 5.83M 73.68M 5.51M 5.39M 234M	P/E 2024	-86x	P/E 2025	-1.62x
Enterprise Value	1.38M 1.53M 1.27M 1.15M 2.18M 143M 2.23M 15.25M 6.08M 76.77M 5.74M 5.61M 244M	EV / Sales 2024	0.84x	EV / Sales 2025	0.47x
Free-Float	98.02%	Yield 2024 *	-	Yield 2025	-

Markets		Quality
Euronext Paris	ALKLA	Real-time
Deutsche Boerse AG	4YA	Delayed
Börse Stuttgart	4YA	Delayed
Boerse Muenchen	4YA	Real-time

10-22	Klarsen Reports Earnings Results for the Half Year Ended June 30, 2026	CI
08-26	Klarsen Reports Earnings Results for the Full Year Ended December 31, 2025	CI
11-03	Klarsen Reports Earnings Results for the Half Year Ended June 30, 2025	CI
29/04/25	Klarsen Reports Earnings Results for the Full Year Ended December 31, 2024	CI
15/10/24	Klarsen Reports Earnings Results for the Half Year Ended June 30, 2024	CI
29/04/24	Klarsen Reports Earnings Results for the Full Year Ended December 31, 2023	CI
15/03/24	Acticor Biotech Raises EUR8 Million to Fund Emergency Stroke Treatment Development	MT
07/11/23	Acticor Biotech’s Phase 2/3 Trial for Stroke Drug Combo on Track for 2024 Results	MT
27/10/23	Klarsen Reports Earnings Results for the Half Year Ended June 30, 2023	CI
27/04/23	Klarsen Reports Earnings Results for the Full Year Ended December 31, 2022	CI
09/03/23	Acticor Biotech Secures Funding Until November After EUR12 Million Equity Raise; Stock Sinks 17%	MT
23/12/22	Acticor Biotech Seeks To Meet With US FDA Over Phase 2/3 Study Of Stroke Drug	MT
14/12/22	Twitter to shut down newsletter product Revue next year	RE

Klarsen Share Price

Stocks

ALKLA

FR0011038348

IT Services & Consulting

Valuation: Klarsen

Chart: Klarsen

Latest news: Klarsen

Press Releases: Klarsen

News in other languages: Klarsen

Quotes and Performance

Price Extremes

Managers and Directors: Klarsen

Latest insider transactions

Other IT Services & Consulting

Financials

Company Profile

Quotes

03-03	Klarsen : ALKLA information relative au nombre total de droits de vote et d'actions composant le capital	PU
02-25	Klarsen : ALKLA-Information relative au nombre de droits de vote et actions composant le capital	PU
12-10	Klarsen : ALKLA-Attribution gratuite de BSA	PU
12-09	Klarsen : ALKLA-ACTIVITE 3T2025	PU
11-27	Klarsen : ALKLA-Résultat augmentation de capital	PU

10-30	KLARSEN: Rapport Financier Semestriel 2026
10-30	Klarsen : Information réglementée – 2026
10-23	Klarsen : Comptes semestriels 2026
10-22	Klarsen : ALKLA-KLARSEN Résultat 1er semestre 2026
10-22	KLARSEN : Résultats semestriels 2026

1 day	-0.25%
1 week	-11.33%
Current month	-13.26%
1 month	-35.23%
3 months	-46.08%
6 months	-31.21%
Current year	-54.03%

1 week	0.38	0.45
1 month	0.38	0.65
Current year	0.22	1.68
1 year	0.22	1.68
3 years	0.22	3.48
5 years	0.22	4.03
10 years	0.11	5.4

Manager	Title	Age	Since
Brice Gazeau CEO	Chief Executive Officer	-	-
Patrice Coffe DFI	Director of Finance/CFO	57	30/06/2008
Jean-Pierre Domingo CTO	Chief Tech/Sci/R&D Officer	-	31/12/2012

Director	Title	Age	Since
Patrice Coffe BRD	Director/Board Member	57	13/06/2010
Gérard Parrou BRD	Director/Board Member	74	26/06/2014
Frédéric Bartoli BRD	Director/Board Member	-	22/03/2011

Date	Insider	Type	Main position	Quantity	% Market Cap.
15/03/22	Parrou Julien	Buy		2,617	0.0790%
28/02/22	Julien Parrou-Duboscq	Buy	Chief Executive Officer	3,011	0.0909%
28/02/22	Julien Parrou-Duboscq	Buy	Chief Executive Officer	3,000	0.0905%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
KLARSEN	-0.25%	-11.33%	-53.60%	-84.83%	1.48M
IBM	+1.65%	-2.49%	-20.95%	+67.45%	231B
SALESFORCE, INC.	+1.75%	-4.17%	-10.99%	+1.09%	176B
ACCENTURE PLC	-1.91%	-4.41%	+4.15%	-19.96%	153B
CLOUDFLARE, INC.	+2.35%	+17.90%	+33.78%	+391.95%	110B
SNOWFLAKE INC.	+1.86%	+4.35%	+11.79%	+91.09%	104B
TATA CONSULTANCY SERVICES LTD.	-0.13%	-1.08%	-18.28%	-25.84%	95.52B
RELX PLC	+0.94%	-1.90%	-7.03%	+1.39%	68.88B
INFOSYS LIMITED	+0.08%	+0.60%	-23.69%	-15.62%	49.86B
HCL TECHNOLOGIES LIMITED	-0.85%	-3.06%	-9.44%	+11.12%	40.62B
Average	+0.55%	+0.08%	-9.43%	+41.78%	103B
Weighted average by Cap.	+0.86%	-0.06%	-4.87%	+60.77%

	2024	2025
Net sales	6.15M 6.82M 5.68M 5.14M 9.72M 640M 9.96M 68.09M 27.14M 343M 25.61M 25.06M 1.09B	6.2M 6.88M 5.73M 5.18M 9.8M 645M 10.04M 68.67M 27.37M 346M 25.83M 25.28M 1.1B
Net income	-47.76K -53K -44.13K -39.89K -75.47K -4.97M -77.34K -529K -211K -2.66M -199K -195K -8.47M	-1.95M -2.17M -1.8M -1.63M -3.08M -203M -3.16M -21.61M -8.61M -109M -8.13M -7.95M -346M
Net Debt	1.08M 1.2M 998K 903K 1.71M 112M 1.75M 11.97M 4.77M 60.23M 4.5M 4.4M 192M	55.36K 61.42K 51.15K 46.24K 87.48K 5.76M 89.64K 613K 244K 3.09M 231K 226K 9.82M